Team starts road trip with injury scare, as Tatis is hit in forearm by a pitch; Padres score three runs in eighth to turn ...

Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 ...

The acquisition of Regulus Therapeutics, a California-based biotechnology company focused on microRNA therapies, by Novartis ...

After announcing successful trial results for its lead mRNA treatment earlier this year, Regulus Therapeutics agreed to be ...

Novartis inks agreement to buy Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD: Basel Friday, May 2, 2025, 14:00 Hrs [IST] Novartis annou ...

Swiss pharmaceutical giant Novartis is poised to expand its profile in the San Diego area, announcing plans to acquire ...

Novartis will acquire Regulus Therapeutics for up to $1.7B, boosting its kidney drug pipeline with lead candidate farabursen.

Ionis Pharmaceuticals unveiled results from a survey conducted by The Harris Poll showing that 91% of surveyed adults living ...

Regulus Therapeutics (RLS) contingent value right may be worth $3-$4 a share in its planned sale to Novartis (NVS), according ...

CVS's decision impacts Eli Lilly shares as it drops Zepbound, while Biogen reports strong sales in rare disease drugs. CVS ...

Novartis has announced that it will be acquiring Regulus Therapeutics in a deal worth $1.7bn, marking a notable boost to the ...

Novartis announces acquisition of Regulus Therapeutics, adding a potential first-in-class miR-17 inhibitor for ADPKD to its ...